<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03119610</url>
  </required_header>
  <id_info>
    <org_study_id>HSC20160661H</org_study_id>
    <nct_id>NCT03119610</nct_id>
  </id_info>
  <brief_title>The Physiologic Effects of Intranasal Oxytocin on Sarcopenic Obesity</brief_title>
  <acronym>INOSO</acronym>
  <official_title>The Physiologic Effects of Intranasal Oxytocin on Sarcopenic Obesity</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sara Espinoza</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The University of Texas Health Science Center at San Antonio</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The University of Texas Health Science Center, Houston</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The University of Texas Medical Branch, Galveston</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>The University of Texas Health Science Center at San Antonio</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Obesity is highly prevalent in older adults and is a major cause of sarcopenia and disability&#xD;
      in older adults. Although exercise can counteract the effects of obesity and sarcopenia, many&#xD;
      have difficulty adhering to an exercise program and the benefits of exercise are variable.&#xD;
      Therefore, there is an urgent need to test novel pharmacologic interventions to prevent&#xD;
      disability and loss of independence. Oxytocin is a pituitary hormone released during&#xD;
      parturition and lactation that is also known to suppress appetite in rodents and humans; and,&#xD;
      recent small studies have found that intranasal oxytocin reduces body weight in adults. We&#xD;
      propose a pilot study of intranasal oxytocin as a novel approach to promote weight loss and&#xD;
      increase muscle mass in older subjects with sarcopenic obesity.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The pilot study will be conducted at 3 sites in 9 visits over a period of 12+ weeks. Older&#xD;
      sedentary subjects will be screened for sarcopenic obesity using a modified consensus&#xD;
      definition and evaluated at baseline for safety labs, glucose tolerance, body composition,&#xD;
      cognition and physical performance, as well as systemic inflammatory markers in blood and&#xD;
      muscle tissue.&#xD;
&#xD;
      Eligible subjects self-administer 24 IU intranasal oxytocin four times a day for 8 weeks.&#xD;
&#xD;
      The study will examine whether the intervention will promote weight loss and preserve muscle&#xD;
      mass, thereby preserving and/or improving physical function in older subjects with sarcopenic&#xD;
      obesity.&#xD;
&#xD;
      Generalized linear mixed effects model will be used to evaluate the effect of oxytocin on the&#xD;
      change of each continuous measure. The effect of oxytocin will be assessed by whether the&#xD;
      time by oxytocin interaction is significantly different from 0 with a 2-sided p-value&lt;0.05.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 22, 2017</start_date>
  <completion_date type="Actual">December 17, 2019</completion_date>
  <primary_completion_date type="Actual">December 17, 2018</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Body Weight</measure>
    <time_frame>Baseline to 8 weeks</time_frame>
    <description>Intranasal oxytocin will promote weight loss and preserve muscle mass</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Fat Mass</measure>
    <time_frame>Baseline to 8 weeks</time_frame>
    <description>Pre- and post-measurements of fat mass by dual energy x-ray absorptiometry (DXA) will be examined for individual change with intranasal oxytocin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Body Mass Index</measure>
    <time_frame>8 weeks</time_frame>
    <description>Pre- and post-measurements of lean mass by DXA will be examined for individual change with intranasal oxytocin. Change in body mass index (BMI).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Glucose Levels Measured Using the Glucose Tolerance Test</measure>
    <time_frame>8 weeks</time_frame>
    <description>Pre- and post-measurements of oral glucose tolerance test for 2-hour plasma glucose will be examined for individual change with intranasal oxytocin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Short Physical Performance Battery (SPPB)</measure>
    <time_frame>Baseline to 8 weeks</time_frame>
    <description>Pre- and post-measurements will be examined for individual change with intranasal oxytocin. This battery of tests is scored on a scale with 3 SPPB calculation components:&#xD;
Ability to stand for 10 seconds with feet in 3 different positions, scored from 0 min to 4 maximum, with a higher score indicating better balance.(3 Balance subsets: side by side stand scored from 0-1; semi-tandem stance scored from 0-1; tandem stance scored from 0-2)&#xD;
Two timed trials of a 3m or 4 m walk (fastest recorded). Scoring is from 0-4, with 0 being unable to walk and 4 indicating a faster walk time.&#xD;
Time to rise from a chair five times is scored from 0-4, with 0 being unable to complete the activity, and 4 indicating that time to complete is less than 11.1 seconds.&#xD;
Total Score is the sum of all 3 scores: Minimum = 0 Maximum = 12. Higher scores indicate better lower extremity function.&#xD;
Difference between baseline and 8 week performance is reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in HbA1c (Hemoglobin A1c)</measure>
    <time_frame>Baseline to 8 weeks</time_frame>
    <description>Pre- and post-measurements will be examined for individual change with intranasal oxytocin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Waist Circumference</measure>
    <time_frame>Baseline to 8 weeks</time_frame>
    <description>Pre- and post-measurements will be examined for individual change with intranasal oxytocin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Total Cholesterol</measure>
    <time_frame>Baseline to 8 weeks</time_frame>
    <description>Pre- and post-measurements will be examined for individual change with intranasal oxytocin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Low Density Lipoproteins (LDL)</measure>
    <time_frame>Baseline to 8 weeks</time_frame>
    <description>Pre- and post-measurements will be examined for individual change with intranasal oxytocin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in High Density Lipoproteins (HDL)</measure>
    <time_frame>Baseline to 8 weeks</time_frame>
    <description>Pre- and post-measurements will be examined for individual change with intranasal oxytocin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Triglycerides</measure>
    <time_frame>Baseline to 8 weeks</time_frame>
    <description>Pre- and post-measurements will be examined for individual change with intranasal oxytocin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Center for Epidemiologic Studies Scale (CES-D)</measure>
    <time_frame>Baseline to 8 weeks</time_frame>
    <description>Pre- and post-measurements will be examined for individual change with intranasal oxytocin. This is measured on a 20 item scale using the following scoring using number of week days:&#xD;
Rarely or none of the time ( less than 1 day)&#xD;
Some or a little of the time (1-2 days)&#xD;
Occasionally or a moderate amount of time (3-4 days)&#xD;
Most or all of the time (5-7 days) SCORING: zero for answers =1), 1 for answers =2), 2 for answers =3) column, 3 for answers =4) The scoring of positive items is reversed. Possible range of scores is zero to 60, with the higher scores indicating the presence of more symptomatology.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Montreal Cognitive Assessment (MoCA)</measure>
    <time_frame>Baseline to 8 weeks</time_frame>
    <description>Pre- and post-measurements will be examined for individual change with intranasal oxytocin. A 30-point test, with a score of 0 or 1 assigned to each item. The minimum score is 0 and the maximum is 30. The higher the score, the less cognitive impairment.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">23</enrollment>
  <condition>Obesity</condition>
  <condition>Sarcopenic Obesity</condition>
  <condition>Sarcopenia</condition>
  <condition>Aging</condition>
  <condition>Sedentary Lifestyle</condition>
  <arm_group>
    <arm_group_label>Oxytocin nasal spray</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oxytocin (Syntocinon), intranasal, 24IU, 4x a day for 8 weeks, self administered</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo nasal spray</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Placebo nasal spray, 4x a day for 8 weeks, self administered</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxytocin nasal spray</intervention_name>
    <description>Self administered Oxytocin nasal spray q.i.d. for 8 weeks versus placebo (normal saline nasal spray)</description>
    <arm_group_label>Oxytocin nasal spray</arm_group_label>
    <other_name>Intranasal oxytocin</other_name>
    <other_name>Syntocinon nasal spray</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo nasal spray</intervention_name>
    <description>Self administered Placebo nasal spray q.i.d. for 8 weeks (normal saline nasal spray)</description>
    <arm_group_label>Placebo nasal spray</arm_group_label>
    <other_name>Saline nasal spray</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  BMI 30-40 kg/m2&#xD;
&#xD;
          -  Sedentary (&lt; 2 strenuous exercise/week)&#xD;
&#xD;
          -  Gait speed &lt; 1 meter/second&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Diabetes (ADA criteria)&#xD;
&#xD;
          -  Heart disease (MI or New York Heart Classification grade III-IV)&#xD;
&#xD;
          -  Poorly controlled hypertension (SBP &gt; 170 or DBP &gt;95 mm/Hg)&#xD;
&#xD;
          -  Anemia (Hematocrit &lt;34%)&#xD;
&#xD;
          -  Renal Disease (Serum Creatinine &gt;1.4, abnormal serum sodium levels, abnormal&#xD;
             urinalysis, or physical exam findings indicative of fluid imbalance; individuals with&#xD;
             underlying disorder of sodium/water balance, such as SIADH, diabetes insipidus, or&#xD;
             psychogenic polydipsia)&#xD;
&#xD;
          -  Liver Disease (AST/ALT/AlkPhos &gt; 2x upper limit of normal)&#xD;
&#xD;
          -  Use of systemic steroid, androgens, or anti-coagulants&#xD;
&#xD;
          -  Active/unstable conditions: inflammatory, thyroid, autoimmune, gastrointestinal (GI),&#xD;
             hematologic, or neoplastic disorders&#xD;
&#xD;
          -  Individuals with underlying seizure disorder or underlying neurologic disorder that&#xD;
             increases seizure risk&#xD;
&#xD;
          -  Cognitive impairment (MiniCog &lt;3), unstable mental illness, substance abuse, or&#xD;
             history of eating disorder&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sara Espinoza, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The University of Texas Health Science Center, San Antonio</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Texas Diabetic Institute</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Espinoza SE, Lee JL, Wang CP, Ganapathy V, MacCarthy D, Pascucci C, Musi N, Volpi E. Intranasal Oxytocin Improves Lean Muscle Mass and Lowers LDL Cholesterol in Older Adults with Sarcopenic Obesity: A Pilot Randomized Controlled Trial. J Am Med Dir Assoc. 2021 Sep;22(9):1877-1882.e2. doi: 10.1016/j.jamda.2021.04.015. Epub 2021 May 21.</citation>
    <PMID>34029521</PMID>
  </results_reference>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>March 22, 2017</study_first_submitted>
  <study_first_submitted_qc>April 13, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 18, 2017</study_first_posted>
  <results_first_submitted>August 24, 2020</results_first_submitted>
  <results_first_submitted_qc>September 25, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">October 22, 2020</results_first_posted>
  <last_update_submitted>October 1, 2021</last_update_submitted>
  <last_update_submitted_qc>October 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>The University of Texas Health Science Center at San Antonio</investigator_affiliation>
    <investigator_full_name>Sara Espinoza</investigator_full_name>
    <investigator_title>Associate Professor of Medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarcopenia</mesh_term>
    <mesh_term>Obesity</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxytocin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>August 3, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/10/NCT03119610/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Oxytocin Nasal Spray</title>
          <description>Oxytocin (Syntocinon), intranasal, 24IU, 4x a day for 8 weeks, self administered&#xD;
Oxytocin nasal spray: Self administered Oxytocin nasal spray q.i.d. for 8 weeks versus placebo (normal saline nasal spray)</description>
        </group>
        <group group_id="P2">
          <title>Placebo Nasal Spray</title>
          <description>Placebo nasal spray, 4x a day for 8 weeks, self administered&#xD;
Placebo nasal spray: Self administered Placebo nasal spray q.i.d. for 8 weeks (normal saline nasal spray)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Oxytocin Nasal Spray</title>
          <description>Oxytocin (Syntocinon), intranasal, 24IU, 4x a day for 8 weeks, self administered&#xD;
Oxytocin nasal spray: Self administered Oxytocin nasal spray q.i.d. for 8 weeks versus placebo (normal saline nasal spray)</description>
        </group>
        <group group_id="B2">
          <title>Placebo Nasal Spray</title>
          <description>Placebo nasal spray, 4x a day for 8 weeks, self administered&#xD;
Placebo nasal spray: Self administered Placebo nasal spray q.i.d. for 8 weeks (normal saline nasal spray)</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="13"/>
            <count group_id="B2" value="10"/>
            <count group_id="B3" value="23"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <description>Participants are included if age 60 or over.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Age, 60 or over</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Body Weight</title>
        <description>Intranasal oxytocin will promote weight loss and preserve muscle mass</description>
        <time_frame>Baseline to 8 weeks</time_frame>
        <population>Two participants withdrew after randomization; 1 in Oxytocin and 1 in Placebo group. Data from these two subjects were not collected.</population>
        <group_list>
          <group group_id="O1">
            <title>Oxytocin Nasal Spray</title>
            <description>Oxytocin (Syntocinon), intranasal, 24IU, 4x a day for 8 weeks, self administered&#xD;
Oxytocin nasal spray: Self administered Oxytocin nasal spray q.i.d. for 8 weeks versus placebo (normal saline nasal spray)</description>
          </group>
          <group group_id="O2">
            <title>Placebo Nasal Spray</title>
            <description>Placebo nasal spray, 4x a day for 8 weeks, self administered&#xD;
Placebo nasal spray: Self administered Placebo nasal spray q.i.d. for 8 weeks (normal saline nasal spray)</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Body Weight</title>
          <description>Intranasal oxytocin will promote weight loss and preserve muscle mass</description>
          <population>Two participants withdrew after randomization; 1 in Oxytocin and 1 in Placebo group. Data from these two subjects were not collected.</population>
          <units>Kilograms</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.54" spread="1.6"/>
                    <measurement group_id="O2" value="0.04" spread="2.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Fat Mass</title>
        <description>Pre- and post-measurements of fat mass by dual energy x-ray absorptiometry (DXA) will be examined for individual change with intranasal oxytocin</description>
        <time_frame>Baseline to 8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Oxytocin Nasal Spray</title>
            <description>Oxytocin (Syntocinon), intranasal, 24IU, 4x a day for 8 weeks, self administered&#xD;
Oxytocin nasal spray: Self administered Oxytocin nasal spray q.i.d. for 8 weeks versus placebo (normal saline nasal spray)</description>
          </group>
          <group group_id="O2">
            <title>Placebo Nasal Spray</title>
            <description>Placebo nasal spray, 4x a day for 8 weeks, self administered&#xD;
Placebo nasal spray: Self administered Placebo nasal spray q.i.d. for 8 weeks (normal saline nasal spray)</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Fat Mass</title>
          <description>Pre- and post-measurements of fat mass by dual energy x-ray absorptiometry (DXA) will be examined for individual change with intranasal oxytocin</description>
          <units>Kilograms</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.2" spread="0.99"/>
                    <measurement group_id="O2" value="-0.1" spread="0.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Body Mass Index</title>
        <description>Pre- and post-measurements of lean mass by DXA will be examined for individual change with intranasal oxytocin. Change in body mass index (BMI).</description>
        <time_frame>8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Oxytocin Nasal Spray</title>
            <description>Oxytocin (Syntocinon), intranasal, 24IU, 4x a day for 8 weeks, self administered&#xD;
Oxytocin nasal spray: Self administered Oxytocin nasal spray q.i.d. for 8 weeks versus placebo (normal saline nasal spray)</description>
          </group>
          <group group_id="O2">
            <title>Placebo Nasal Spray</title>
            <description>Placebo nasal spray, 4x a day for 8 weeks, self administered&#xD;
Placebo nasal spray: Self administered Placebo nasal spray q.i.d. for 8 weeks (normal saline nasal spray)</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Body Mass Index</title>
          <description>Pre- and post-measurements of lean mass by DXA will be examined for individual change with intranasal oxytocin. Change in body mass index (BMI).</description>
          <units>kg/m2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.8" spread="3.5"/>
                    <measurement group_id="O2" value="36.8" spread="3.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Glucose Levels Measured Using the Glucose Tolerance Test</title>
        <description>Pre- and post-measurements of oral glucose tolerance test for 2-hour plasma glucose will be examined for individual change with intranasal oxytocin</description>
        <time_frame>8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Oxytocin Nasal Spray</title>
            <description>Oxytocin (Syntocinon), intranasal, 24IU, 4x a day for 8 weeks, self administered&#xD;
Oxytocin nasal spray: Self administered Oxytocin nasal spray q.i.d. for 8 weeks versus placebo (normal saline nasal spray)</description>
          </group>
          <group group_id="O2">
            <title>Placebo Nasal Spray</title>
            <description>Placebo nasal spray, 4x a day for 8 weeks, self administered&#xD;
Placebo nasal spray: Self administered Placebo nasal spray q.i.d. for 8 weeks (normal saline nasal spray)</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Glucose Levels Measured Using the Glucose Tolerance Test</title>
          <description>Pre- and post-measurements of oral glucose tolerance test for 2-hour plasma glucose will be examined for individual change with intranasal oxytocin</description>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Fasting glucose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.36" spread="10.18"/>
                    <measurement group_id="O2" value="2.85" spread="6.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2-hour glucose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.15" spread="31.126"/>
                    <measurement group_id="O2" value="-3.375" spread="14.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Short Physical Performance Battery (SPPB)</title>
        <description>Pre- and post-measurements will be examined for individual change with intranasal oxytocin. This battery of tests is scored on a scale with 3 SPPB calculation components:&#xD;
Ability to stand for 10 seconds with feet in 3 different positions, scored from 0 min to 4 maximum, with a higher score indicating better balance.(3 Balance subsets: side by side stand scored from 0-1; semi-tandem stance scored from 0-1; tandem stance scored from 0-2)&#xD;
Two timed trials of a 3m or 4 m walk (fastest recorded). Scoring is from 0-4, with 0 being unable to walk and 4 indicating a faster walk time.&#xD;
Time to rise from a chair five times is scored from 0-4, with 0 being unable to complete the activity, and 4 indicating that time to complete is less than 11.1 seconds.&#xD;
Total Score is the sum of all 3 scores: Minimum = 0 Maximum = 12. Higher scores indicate better lower extremity function.&#xD;
Difference between baseline and 8 week performance is reported.</description>
        <time_frame>Baseline to 8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Oxytocin Nasal Spray</title>
            <description>Oxytocin (Syntocinon), intranasal, 24IU, 4x a day for 8 weeks, self administered&#xD;
Oxytocin nasal spray: Self administered Oxytocin nasal spray q.i.d. for 8 weeks versus placebo (normal saline nasal spray)</description>
          </group>
          <group group_id="O2">
            <title>Placebo Nasal Spray</title>
            <description>Placebo nasal spray, 4x a day for 8 weeks, self administered&#xD;
Placebo nasal spray: Self administered Placebo nasal spray q.i.d. for 8 weeks (normal saline nasal spray)</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Short Physical Performance Battery (SPPB)</title>
          <description>Pre- and post-measurements will be examined for individual change with intranasal oxytocin. This battery of tests is scored on a scale with 3 SPPB calculation components:&#xD;
Ability to stand for 10 seconds with feet in 3 different positions, scored from 0 min to 4 maximum, with a higher score indicating better balance.(3 Balance subsets: side by side stand scored from 0-1; semi-tandem stance scored from 0-1; tandem stance scored from 0-2)&#xD;
Two timed trials of a 3m or 4 m walk (fastest recorded). Scoring is from 0-4, with 0 being unable to walk and 4 indicating a faster walk time.&#xD;
Time to rise from a chair five times is scored from 0-4, with 0 being unable to complete the activity, and 4 indicating that time to complete is less than 11.1 seconds.&#xD;
Total Score is the sum of all 3 scores: Minimum = 0 Maximum = 12. Higher scores indicate better lower extremity function.&#xD;
Difference between baseline and 8 week performance is reported.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" spread="1.446"/>
                    <measurement group_id="O2" value="0.625" spread="1.598"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in HbA1c (Hemoglobin A1c)</title>
        <description>Pre- and post-measurements will be examined for individual change with intranasal oxytocin</description>
        <time_frame>Baseline to 8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Oxytocin Nasal Spray</title>
            <description>Oxytocin (Syntocinon), intranasal, 24IU, 4x a day for 8 weeks, self administered&#xD;
Oxytocin nasal spray: Self administered Oxytocin nasal spray q.i.d. for 8 weeks versus placebo (normal saline nasal spray)</description>
          </group>
          <group group_id="O2">
            <title>Placebo Nasal Spray</title>
            <description>Placebo nasal spray, 4x a day for 8 weeks, self administered&#xD;
Placebo nasal spray: Self administered Placebo nasal spray q.i.d. for 8 weeks (normal saline nasal spray)</description>
          </group>
        </group_list>
        <measure>
          <title>Change in HbA1c (Hemoglobin A1c)</title>
          <description>Pre- and post-measurements will be examined for individual change with intranasal oxytocin</description>
          <units>Percentage</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.05" spread="0.1857"/>
                    <measurement group_id="O2" value="0.286" spread="0.1254"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Waist Circumference</title>
        <description>Pre- and post-measurements will be examined for individual change with intranasal oxytocin</description>
        <time_frame>Baseline to 8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Oxytocin Nasal Spray</title>
            <description>Oxytocin (Syntocinon), intranasal, 24IU, 4x a day for 8 weeks, self administered&#xD;
Oxytocin nasal spray: Self administered Oxytocin nasal spray q.i.d. for 8 weeks versus placebo (normal saline nasal spray)</description>
          </group>
          <group group_id="O2">
            <title>Placebo Nasal Spray</title>
            <description>Placebo nasal spray, 4x a day for 8 weeks, self administered&#xD;
Placebo nasal spray: Self administered Placebo nasal spray q.i.d. for 8 weeks (normal saline nasal spray)</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Waist Circumference</title>
          <description>Pre- and post-measurements will be examined for individual change with intranasal oxytocin</description>
          <units>centimeteres</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.6958" spread="4.8662"/>
                    <measurement group_id="O2" value="-1.373" spread="2.1997"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Total Cholesterol</title>
        <description>Pre- and post-measurements will be examined for individual change with intranasal oxytocin</description>
        <time_frame>Baseline to 8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Oxytocin Nasal Spray</title>
            <description>Oxytocin (Syntocinon), intranasal, 24IU, 4x a day for 8 weeks, self administered&#xD;
Oxytocin nasal spray: Self administered Oxytocin nasal spray q.i.d. for 8 weeks versus placebo (normal saline nasal spray)</description>
          </group>
          <group group_id="O2">
            <title>Placebo Nasal Spray</title>
            <description>Placebo nasal spray, 4x a day for 8 weeks, self administered&#xD;
Placebo nasal spray: Self administered Placebo nasal spray q.i.d. for 8 weeks (normal saline nasal spray)</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Total Cholesterol</title>
          <description>Pre- and post-measurements will be examined for individual change with intranasal oxytocin</description>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.18" spread="17.417"/>
                    <measurement group_id="O2" value="-1.143" spread="16.056"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Low Density Lipoproteins (LDL)</title>
        <description>Pre- and post-measurements will be examined for individual change with intranasal oxytocin</description>
        <time_frame>Baseline to 8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Oxytocin Nasal Spray</title>
            <description>Oxytocin (Syntocinon), intranasal, 24IU, 4x a day for 8 weeks, self administered&#xD;
Oxytocin nasal spray: Self administered Oxytocin nasal spray q.i.d. for 8 weeks versus placebo (normal saline nasal spray)</description>
          </group>
          <group group_id="O2">
            <title>Placebo Nasal Spray</title>
            <description>Placebo nasal spray, 4x a day for 8 weeks, self administered&#xD;
Placebo nasal spray: Self administered Placebo nasal spray q.i.d. for 8 weeks (normal saline nasal spray)</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Low Density Lipoproteins (LDL)</title>
          <description>Pre- and post-measurements will be examined for individual change with intranasal oxytocin</description>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.727" spread="16.224"/>
                    <measurement group_id="O2" value="4.1429" spread="11.539"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in High Density Lipoproteins (HDL)</title>
        <description>Pre- and post-measurements will be examined for individual change with intranasal oxytocin</description>
        <time_frame>Baseline to 8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Oxytocin Nasal Spray</title>
            <description>Oxytocin (Syntocinon), intranasal, 24IU, 4x a day for 8 weeks, self administered&#xD;
Oxytocin nasal spray: Self administered Oxytocin nasal spray q.i.d. for 8 weeks versus placebo (normal saline nasal spray)</description>
          </group>
          <group group_id="O2">
            <title>Placebo Nasal Spray</title>
            <description>Placebo nasal spray, 4x a day for 8 weeks, self administered&#xD;
Placebo nasal spray: Self administered Placebo nasal spray q.i.d. for 8 weeks (normal saline nasal spray)</description>
          </group>
        </group_list>
        <measure>
          <title>Change in High Density Lipoproteins (HDL)</title>
          <description>Pre- and post-measurements will be examined for individual change with intranasal oxytocin</description>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.000" spread="2.8983"/>
                    <measurement group_id="O2" value="0.1429" spread="3.8408"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Triglycerides</title>
        <description>Pre- and post-measurements will be examined for individual change with intranasal oxytocin</description>
        <time_frame>Baseline to 8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Oxytocin Nasal Spray</title>
            <description>Oxytocin (Syntocinon), intranasal, 24IU, 4x a day for 8 weeks, self administered&#xD;
Oxytocin nasal spray: Self administered Oxytocin nasal spray q.i.d. for 8 weeks versus placebo (normal saline nasal spray)</description>
          </group>
          <group group_id="O2">
            <title>Placebo Nasal Spray</title>
            <description>Placebo nasal spray, 4x a day for 8 weeks, self administered&#xD;
Placebo nasal spray: Self administered Placebo nasal spray q.i.d. for 8 weeks (normal saline nasal spray)</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Triglycerides</title>
          <description>Pre- and post-measurements will be examined for individual change with intranasal oxytocin</description>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-16.82" spread="23.828"/>
                    <measurement group_id="O2" value="-26.29" spread="46.903"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Center for Epidemiologic Studies Scale (CES-D)</title>
        <description>Pre- and post-measurements will be examined for individual change with intranasal oxytocin. This is measured on a 20 item scale using the following scoring using number of week days:&#xD;
Rarely or none of the time ( less than 1 day)&#xD;
Some or a little of the time (1-2 days)&#xD;
Occasionally or a moderate amount of time (3-4 days)&#xD;
Most or all of the time (5-7 days) SCORING: zero for answers =1), 1 for answers =2), 2 for answers =3) column, 3 for answers =4) The scoring of positive items is reversed. Possible range of scores is zero to 60, with the higher scores indicating the presence of more symptomatology.</description>
        <time_frame>Baseline to 8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Oxytocin Nasal Spray</title>
            <description>Oxytocin (Syntocinon), intranasal, 24IU, 4x a day for 8 weeks, self administered&#xD;
Oxytocin nasal spray: Self administered Oxytocin nasal spray q.i.d. for 8 weeks versus placebo (normal saline nasal spray)</description>
          </group>
          <group group_id="O2">
            <title>Placebo Nasal Spray</title>
            <description>Placebo nasal spray, 4x a day for 8 weeks, self administered&#xD;
Placebo nasal spray: Self administered Placebo nasal spray q.i.d. for 8 weeks (normal saline nasal spray)</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Center for Epidemiologic Studies Scale (CES-D)</title>
          <description>Pre- and post-measurements will be examined for individual change with intranasal oxytocin. This is measured on a 20 item scale using the following scoring using number of week days:&#xD;
Rarely or none of the time ( less than 1 day)&#xD;
Some or a little of the time (1-2 days)&#xD;
Occasionally or a moderate amount of time (3-4 days)&#xD;
Most or all of the time (5-7 days) SCORING: zero for answers =1), 1 for answers =2), 2 for answers =3) column, 3 for answers =4) The scoring of positive items is reversed. Possible range of scores is zero to 60, with the higher scores indicating the presence of more symptomatology.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.375" spread="2.1860"/>
                    <measurement group_id="O2" value="0.2222" spread="2.7285"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Montreal Cognitive Assessment (MoCA)</title>
        <description>Pre- and post-measurements will be examined for individual change with intranasal oxytocin. A 30-point test, with a score of 0 or 1 assigned to each item. The minimum score is 0 and the maximum is 30. The higher the score, the less cognitive impairment.</description>
        <time_frame>Baseline to 8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Oxytocin Nasal Spray</title>
            <description>Oxytocin (Syntocinon), intranasal, 24IU, 4x a day for 8 weeks, self administered&#xD;
Oxytocin nasal spray: Self administered Oxytocin nasal spray q.i.d. for 8 weeks versus placebo (normal saline nasal spray)</description>
          </group>
          <group group_id="O2">
            <title>Placebo Nasal Spray</title>
            <description>Placebo nasal spray, 4x a day for 8 weeks, self administered&#xD;
Placebo nasal spray: Self administered Placebo nasal spray q.i.d. for 8 weeks (normal saline nasal spray)</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Montreal Cognitive Assessment (MoCA)</title>
          <description>Pre- and post-measurements will be examined for individual change with intranasal oxytocin. A 30-point test, with a score of 0 or 1 assigned to each item. The minimum score is 0 and the maximum is 30. The higher the score, the less cognitive impairment.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0000" spread="1.5954"/>
                    <measurement group_id="O2" value="0.4444" spread="1.3333"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>8 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Oxytocin Nasal Spray</title>
          <description>Oxytocin (Syntocinon), intranasal, 24IU, 4x a day for 8 weeks, self administered&#xD;
Oxytocin nasal spray: Self administered Oxytocin nasal spray q.i.d. for 8 weeks versus placebo (normal saline nasal spray)</description>
        </group>
        <group group_id="E2">
          <title>Placebo Nasal Spray</title>
          <description>Placebo nasal spray, 4x a day for 8 weeks, self administered&#xD;
Placebo nasal spray: Self administered Placebo nasal spray q.i.d. for 8 weeks (normal saline nasal spray)</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Upset stomach</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Decreased Appetite</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Loose stool</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Increased bowel movement</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Tiredness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Flu like symptoms</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Neck Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Muscle Aches</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Muscle spasms, hands</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Muscle spasms, legs</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Leg cramps</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Muscle cramps</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="12"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="12"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Lightheaded</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Confusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Delirium</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Bladder disturbance</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic Rhinitis</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Nasal Irritation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Sinus Disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Postnasal Drip</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Sore Throat</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Throat itching</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin Rash</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Bruise related to biopsy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Sara Espinoza, MD</name_or_title>
      <organization>UT Health San Antonio</organization>
      <phone>210-617-5197</phone>
      <email>espinozas2@uthscsa.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

